A court has ordered Medtronic to pay almost $382 million to Applied Medical Resources Corporation following an antitrust ruling against the medical device giant, according to a report by MobiHealthNews.

The award closes a chapter in litigation between two major players in the surgical device market. Applied Medical, a California-based manufacturer of surgical access and laparoscopic products, pursued claims that Medtronic abused its market position to exclude rivals and protect its device business. The nearly $382 million figure represents the monetary relief the court directed Medtronic to pay.

Why the Award Matters

Antitrust verdicts of this size against medical device manufacturers remain relatively rare. The award signals continued willingness by US courts and juries to hold dominant suppliers accountable when competitors present credible evidence of exclusionary conduct.

For Applied Medical, the ruling vindicates a long-running challenge to the conduct of a far larger competitor. For Medtronic, the nearly $382 million payment adds financial exposure to the reputational and compliance costs that accompany an antitrust loss.

Practical Consequences for Practitioners

The ruling has several immediate implications for antitrust and healthcare litigation practices. First, it confirms that competitor suits — not just class actions by purchasers — can produce substantial monetary outcomes in the medical device sector. Defendants in dominant market positions should expect plaintiffs' counsel to cite the award when valuing exclusionary-conduct claims.

Second, the case is a reminder that distribution and contracting practices in the medical device industry, including bundled arrangements and loyalty incentives, remain a focus of private antitrust enforcement. Companies operating in concentrated device markets should review their contracting structures against exclusionary-conduct risk.

Third, the size of the award will likely influence settlement dynamics in pending and future antitrust disputes involving device manufacturers. A near-$382 million judicially ordered payment resets the benchmark for what competitors may demand at the negotiating table.

Finally, counsel for Medtronic will need to assess post-trial options, including motions challenging the verdict and any available appellate routes. Until those avenues are exhausted or waived, the final amount payable may remain subject to adjustment.

Sector Context

The medical device industry has faced sustained antitrust scrutiny in recent years, both from private litigants and from regulators examining how large manufacturers leverage bundled purchasing agreements, exclusive dealing, and market share advantages. The Applied Medical award against Medtronic fits that broader pattern of enforcement pressure on dominant suppliers.

For hospital procurement teams and group purchasing organizations, the ruling may also carry indirect consequences. Purchasers watching antitrust outcomes among their suppliers often revisit contract terms and supplier-diversification strategies when exclusionary conduct claims succeed.

What Comes Next

Attention now turns to whether Medtronic pursues an appeal and whether the ruling prompts additional antitrust claims from other competitors in the surgical device market. Applied Medical, as the prevailing party, will focus on collecting the award and on any injunctive or forward-looking remedies the court may have ordered.

Practitioners advising clients in the medical device space should monitor post-trial filings in the case, both for the eventual disposition of the award and for any legal reasoning that could shape future exclusionary-conduct claims in the sector.